Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$56.17 USD

56.17
164,232

-0.16 (-0.28%)

Updated Aug 30, 2024 11:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod

by Kinjel Shah

Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.

Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1

by Zacks Equity Research

Alnylam (ALNY) reports narrower-than-expected loss in the first quarter of 2019. Also, sales beat estimates.

What's in the Cards for Novavax (NVAX) This Earnings Season?

by Zacks Equity Research

Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.

BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat

by Zacks Equity Research

BioMarin's (BMRN) earnings and revenues surpass estimates in the first quarter.

Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales

by Zacks Equity Research

Sanofi's first-quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales.

Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study

by Zacks Equity Research

Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.

Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth

by Zacks Equity Research

Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.

Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics

by Zacks Equity Research

Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).

Inovio Closes Enrollment in Brain Cancer Study Before Time

by Zacks Equity Research

Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.

Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval

by Zacks Equity Research

Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.

AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes

by Zacks Equity Research

AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.

Lilly (LLY) Signs New Immunology Deal With Private Biotech

by Zacks Equity Research

Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.

Ascendis Pivotal Growth Hormone Deficiency Study Data Positive

by Zacks Equity Research

Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.

Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug

by Zacks Equity Research

FDA issues complete response letter for Lexicon Pharmaceuticals (LXRX) and partner Sanofi's marketing application for type I diabetes candidate, Zynquista.

AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes

by Zacks Equity Research

AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.

Biogen Stock Crashes on Termination of Alzheimer's Studies

by Zacks Equity Research

Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.

Emergent Begins Phase III Study on Anthrax Vaccine AV7909

by Zacks Equity Research

Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.

Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent

by Zacks Equity Research

Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.

Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study

by Zacks Equity Research

Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.

Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News

by Zacks Equity Research

Key highlights of the past week are regulatory and pipeline developments.

Should Value Investors Consider Sanofi (SNY) Stock Now?

by Zacks Equity Research

Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.

Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion

by Zacks Equity Research

The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.

Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps

by Zacks Equity Research

Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.

Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA

by Zacks Equity Research

The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.

Mark Vickery headshot

Top Stock Reports for Salesforce, Booking Holdings & VMware

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including salesforce (CRM), Booking Holdings (BKNG) and VMware (VMW).